The ADVANCE trial randomised 43 patients with unresectable EGFR-mutated stage III lung cancer to aumolertinib with radiotherapy or chemotherapy with radiotherapy, and stopped early. Median progression-free survival was 34.0 months in the aumolertinib arm against 7.4 months with chemotherapy and radiotherapy. In 125 patients outside the trial, a targeted drug with radiotherapy did as well with or without chemotherapy, both better than chemoradiotherapy alone.
Why it is interesting: Tests whether a targeted drug can replace chemotherapy alongside radiotherapy, with overall survival still immature at early stopping.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.